
- Patients receiving glucocorticoid treatment are prone to develop metabolic complications.
- In a randomised controlled trial of metformin targeting metabolic complications in non-diabetic patients needing glucocorticoid (prednisone, prednisolone or methylprednisolone) therapy, metformin (850 mg once daily for one week followed by 850 mg twice daily for three weeks) exerted a beneficial effect on glycaemic control.

**Metformin seems to be a promising drug for preventing metabolic side effects during systemic glucocorticoid treatment.**